Reading VSEE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VSEE free→Reading VSEE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VSEE free→QuarterlyIQ Insights · VSEE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Unregistered Sales of Equity Securities. The disclosure set forth above in
Entry into a Material Definitive Agreement. Standby Equity Purchase Agreement On June 2, 2026 (the “Effective Date”), VSee Health, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”). Capitalized terms used herein, but not otherwise defined, have the meaning given to such terms in the SEPA, a copy of which is filed herewith as Exhibit 10.1. Pursuant to the SEPA, and upon the satisfacti…
Entry into a Material Definitive Agreement. Note Financing On June 8, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “SPA”) with an institutional investor (the “Holder”). Pursuant to the SPA, the Company issued the holder an 8% original issue discount secured promissory note in favor of the Holder, in the aggregate principal amount of $271,739.13 (including the original issue discount of $21,739.13) (the “Promissory Note”). Th…
The Promissory Note to be issued in the connection with the Purchase Agreement will be issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a)(2) of the Securities Act, and other applicable requirements were met. Neither this Current Report on Form 8-K nor any o…
Chief Executive Officer — Mr. Chen: Mr. Chen resigned and was replaced by Dr. Imoigele Aisiku.
The Common Stock to be issued in the connection with the Purchase Agreement will be issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a)(2) of the Securities Act, and other applicable requirements were met. Neither this Current Report on Form 8-K nor any of th…
Entry into a Material Definitive Agreement. On May 31, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Milton Chen, the Company’s co-Chief Executive Officer and Chairman of the Board and the Chief Executive Officer of VSee Lab, Inc., a Delaware Corporation and wholly-owned subsidiary of the Company (“VSee Lab”). Pursuant to the Purchase Agreement, Mr. Chen agreed to purchase, and the Company agreed to sell…
Filed as Exhibit 99.1 to this Current Report on Form 8-K is the unaudited pro forma condensed consolidated balance sheet of the Company as of March 31, 2026 and the unaudited pro forma condensed consolidated statements of operations of the Company for the three months ended March 31, 2026, and the year ended December 31, 2025, in each case giving effect to the transaction described under
Entry into a Material Definitive Agreement. Managed Services Agreement On December 26, 2025, VSee Health, Inc., a Delaware Corporation (the “Company”) and iDoc Virtual Telehealth Solutions, Inc., a Texas Corporation and wholly-owned subsidiary of the Company, entered into a Managed Services Agreement with GoMyRx, Inc., a Wyoming corporation (“GMRx”), a digital prescription fulfillment platform and affiliate company of the GoMyDocs healthcare ecosystem (the “MSA”). Pursuant to the MSA, the Com…
Entry into a Material Definitive Agreement. On November 25, 2025, VSee Health, Inc. (the “Company”) and a single institutional and accredited investor (the “Purchaser”) entered into a securities purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell to the Purchaser an aggregate of 9,836,065 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), or pre-funded warrants exercisable for $0.0001 per share in li…
The Company will issue the Shares, the Pre-Funded Warrants, the Warrants, the Pre-Funded Warrant Shares and the Warrant Shares in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from t…
Entry into a Material Definitive Agreement On November 13, 2025, VSee Health, Inc. (the “ Company ”), entered into an exchange agreement (the “ Agreement ”) with an accredited institutional investor (the “ Holder ”), whereby the Holder agreed to exchange a certain promissory note, in the principal amount (including the original issue discount of $55,555.56) of $555,555.56 and with a current balance of $611,878.22, for 941,352 shares of the Company’s common stock, par value $0.0001 per share.…
Unregistered Sales of Equity Securities The information set forth in “
Entry into a Material Definitive Agreement On October 29, 2025, VSee Health, Inc. (the “Company”), entered into a convertible note purchase agreement (the “CNPA”) with an accredited institutional investor (the “Investor”), whereby the Investor purchased a convertible promissory note in the initial principal amount of $217,391 (the “Note”) and 50,000 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) for an aggregate purchase price of $201,000. Pursuant to the C…
Unregistered Sales of Equity Securities. The information provided in “
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement The information provided in “
Entry into a Material Definitive Agreement On October 29, 2025, VSee Health, Inc. (the “Company”), entered into a warrant exchange agreement (the “Agreement”) with an accredited institutional investor (the “Holder”), whereby the Holder agreed to exercise approximately 130,000 outstanding warrants issued by the Company in connection with its initial public offering for cash, pursuant to the terms of such warrants, as well as exchange an additional 2,250,000 outstanding warrants issued by the C…
Entry into a Material Definitive Agreement On October 21, 2025, VSee Health, Inc. (the “Company”), entered into an Amendment No. 1 (the “Amendment”) to the senior secured convertible promissory note, issued on September 30, 2024 (the “Note”) in the original principal amount of $2,222,222 (the “Note”), with the accredited and institutional investor (the “Holder”). The Note was previously issued by the Company to the Holder pursuant to the securities purchase agreement, dated September 30, 2024…
Entry into a Material Definitive Agreement Financing On October 20, 2025, VSee Health, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) with an accredited institutional investor (the “Investor”) pursuant to which the Company issued to the Investor a secured note in the aggregate principal amount of $133,333.33 (the “Note”) for a purchase price of $120,000. The Note bears interest at the rate of 5% per annum and matures on May 20, 2026. The Note is no…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. The information provided in
Changes in Registrant’s Certifying Accountant. Dismissal of Prior Independent Registered Public Accounting Firm On September 15, 2025, VSee Health Inc., a Delaware Corporation (the “Company”), and the Company’s board of directors (the “Board”) notified WithumSmith+Brown, PC (“Withum”), the Company’s independent registered public accounting firm, of its decision to dismiss Withum as the Company’s independent registered public accounting firm, effective immediately. Although their audit was not…
Entry into a Material Definitive Agreement On October 9, 2025, VSee Health, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) with an accredited institutional investor (the “Investor”) pursuant to which the Company issued to the Investor a secured note in the aggregate principal amount of $133,333.33 (the “Note”) for a purchase price of $120,000. The Note bears interest at the rate of 5% per annum and matures on May 8, 2026. The Note is not convertibl…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. The information provided in
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 24, 2025, VSee Health, Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued lis…
Importance-ranked changes since the prior daily snapshot.
Confidence changed from 'low' to 'medium'.
Signal changed from 'None' to 'cautious'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.